Le médicament du mois. Le tacrolimus topique (Protopic).

Administration, Cutaneous; Dermatitis, Atopic/drug therapy/immunology/pathology; Drug Tolerance; Humans; Immunosuppressive Agents/immunology/pharmacokinetics/therapeutic use; Risk Factors; Skin Absorption/drug effects; Tacrolimus/immunology/pharmacology/therapeutic use; Th1 Cells/drug effects; Th2 Cells/drug effects; Treatment Outcome

Abstract :

[en] Tacrolimus is a potent inhibitor of immune mechanisms. It belongs to the macrolactam group. It inhibits the release of both Th1 and Th2 cytokines. It proves to be efficacious after topical application in the treatment of atopic dermatitis. In this indication, tacrolimus challenges topical corticosteroids. Irritation risks are present. The local immuno-depression can boost disseminated infections including herpes. The risk to promote photocarcinogenesis on the long term, and that bound to chronic resorption remain theoretical concerns that have not been assessed so far.

Disciplines :

Dermatology

Author, co-author :

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Paquet, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Le médicament du mois. Le tacrolimus topique (Protopic).

Alternative titles :

[en] Drug of month. Topical tacrolimus (Protopic).

Publication date :

2002

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

552-5

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 March 2009

Statistics

Number of views

296 (1 by ULiège)

Number of downloads

452 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Ruzicka T, Assmann T, Homey B. - Tacrolimus: the drug for the turn of the millennium? Arch Dermatol, 1999, 135, 574-580.
Borhövd E, Burgdorf WH, Wollenberg A. - Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol, 2001, 45, 736-743.
Homey B, Assmann T, Vohr HW, et al. - Topical FK506 supresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol, 1998, 160, 5331-5340.
Wesselborg S, Fruman DA, Sagoo JK, et al. - Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem, 1996, 271, 1274-1277.
Schneider G, Heinfling A, Klein HS, et al. - The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promotor. Immunobiology, 1995, 193, 268-272.
Michel G, Ried C, Beetz A. - FK-506 blocks expression of interleukin-8 receptor in normal human keratinocytes. J Invest Dermatol, 1993, 100, 449.
Wollenberg A, Kraft S, Hanau D, et al. - Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol, 1996, 106, 446-453.
Panhans-Gross A, Novak N, Kraft S, et al. - Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol, 2001, 107, 345-352.
Wollenberg A, Sharma S, von Bubnoff D, et al. - Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol, 2001, 107, 519-525.
De Paulis A, Stellato C, Cirillo R, et al. - Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol, 1992, 99, 723-728.
The European FK506 Multicentre Psoriasis Study Group. - Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double blind, placebo-controlled study. Arch Dermatol, 1996, 132, 419-423.
Willemaers V, Stas I, Piérard-Franchimont C, et al. - La dermatite atopique. Rev Med Liège, 1998, 53, 67-70.
Piérard GE, Piérard-Franchimont C. - Des herbes pour la dermatite atopique: phytothérapie de l'apprenti sorcier ou mascarade trompeuse et coupable? Rev Med Liège, 1999, 54, 539-540.
Aoyama H, Tabata N, Tanaka M, et al. - Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK-506 ointment. Br J Dermatol, 1995, 133, 494-496.
Ruzicka T, Bieber T, Schöpf E, et al. - A short term trial of tacrolimus ointment for atopic dermatis. N Engl J Med, 1997, 337, 816-821.
Marone G. - Tacrolimus ointment for atopic dermatitis. N Engl J Med, 1998, 393, 1788.
Fleischer AB Jr. - Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Aller Clin Immunol, 1999, 104, S126-S130.
Assmann T, Homey B, Ruzicka T. - Topical tacrolimus for the treatment of inflammatory skin diseases. Exp Opin Pharmacother, 2001, 2, 1167-1175.
Cheer SM, Plosker GL. - Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol, 2001, 2, 389-406.
Gianni LM, Sulli MM. - Topical tacrolimus in the treatment of atopic dermatitis. Ann Pharmacother, 2001, 35, 943-946.
Kawakami T, Soma Y, Morita E, et al. - Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology, 2001, 203, 32-37.
Nghiem P. - "Topical immunomodulators?" introducing old friends and a new ally, tacrolimus. J Am Acad Dermatol, 2001, 44, 111-113.
Paller A, Eichenfield L, Leung D, et al. - A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol, 2001, 44 (suppl 1), S47-S57.
Skaehill PA. - Tacrolimus in dermatologic disorders. Ann Pharmacother, 2001, 35, 582-588.
Soter N, Fleischer A, Webster G, et al. - Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. II. Safety. J Am Acad Dermatol, 2001, 44 (suppl 1), S39-S46.
Sugiura H, Uehara M, Hoshino N, et al. - An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. Br J Dermatol, 2001, 145, 795-798.
Lacour JP. - Tacrolimus topique en dermatologie: que peut-on en attendre? Ann Dermatol Venereol, 2001, 128, 1291-1294.
Lübbe J. - Topical tacrolimus for atopic dermatitis: euphoria and vigilance. Dermatology, 2001, 203, 1-2.
Kang S, Lucky AW, Pariser D, et al. - Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol, 2001, 44, S58-S64.
Reitamo S, Rissanen J, Remitz A, et al. - Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol, 1998, 111, 396-398.
Letawe C, Piérard-Franchimont C, Piérard GE. - Squamometry in rating the efficacy of topical corticosteroids in atopic dermatitis. Eur J Clin Pharmacol, 1996, 51, 253-258.
Lauerma AI, Surber C, Maibach HI. - Absorption topical tacrolimus (FK-506) in vitro through human skin comparison with Cyclosporin A. Skin Pharmacol, 1997, 10 (5-6), 230-234.
Kawashima M, Nakagawa H, Ohtsuki M, et al. - Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet, 1996, 348, 1240-1241.
Petit L, Braham C, Nikkels C, et al. - Comment je traite .... un herpés labial récurrent. Rev Med Liége, 2002, 57, 67-71.
Reitamo S, Wollenberg A, Schöpf E, et al. - Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol, 2000, 136, 999-1006.
Lubbe J, Pournaras CC, Saurat JH. - Eczma herpeticum during treatment of atopic dermatitis with 0.1 tacrolimus ointment. Dermatology, 2000, 201, 249-251.
Drake L, Prendergast M, Maher R, et al. - The impact of tacrolimus ointment of health-related quality of life of adult and pediatric patient with atopic dermatitis. J Am Acad Dermatol, 2001, 44, S65-72.